Advice

Appendix: search strategy and evidence selection

Appendix: search strategy and evidence selection

Search strategy

For the clinical evidence

Embase 1980 to 2015 October 22, Ovid MEDLINE(R) In‑Process & Other Non‑Indexed Citations and Ovid MEDLINE(R) 1946 to Present; searched 22 October 2015

Search strategy 1: Device and Coronary Artery Disease

1. CT.mp.

2. computed tomography.mp.

3. Coronary Artery Disease.mp. or Coronary Artery Disease/

4. Coronary Artery Disease/ or Coronary Disease/ or Coronary Angiography/

5. CAD.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

6. myocardial infarction.mp. or Myocardial Infarction/

7. myocardial ischemia.mp. or Myocardial Ischemia/

8. Aquilion.mp.

9. Prime.mp.

10. Toshiba.mp.

11. 1 or 2

12. 3 or 4 or 5 or 6 or 7

13. 8 or 9 or 10

14. 11 and 12 and 13

15. limit 14 to yr="2012 ‑ current"

16. limit 15 to english language

Search strategy 2: Population and CT

1. CT.tw.

2. computed tomography.tw.

3. Coronary Artery Disease.tw. or Coronary Artery Disease/

4. Coronary Artery Disease/ or Coronary Disease/ or Coronary Angiography/

5. (coronary adj2 disease).tw.

6. CAD.tw.

7. myocardial infarction.tw. or Myocardial Infarction/

8. myocardial ischemia.tw. or Myocardial Ischemia/

9. high heart rate.tw.

10. arrhythmia.tw.

11. (tachycardia or tachyarrhythmia).tw.

12. (obesity or obese).tw.

13. stents.tw.

14. bypass grafts.tw.

15. calcium score.tw.

16. 1 or 2

17. 3 or 4 or 5 or 6

18. 7 or 8 or 9 or 11 or 12 or 13 or 14 or 15

19. 16 and 17 and 18

20. 19 not (perfusion or gene or neuro* or immuno* or simulat* or child* or youth or baby or infant).tw.

21. limit 20 to english language

22. limit 21 to yr="2012‑current"

For the economic evidence

Embase 1974 to 2015 October 28, Ovid MEDLINE(R) In‑Process & Other Non‑Indexed Citations and Ovid MEDLINE(R) 1946 to Present; Searched on 29October 2015

1. CT.mp.

2. computed tomography.mp.

3. Coronary Artery Disease.mp. or Coronary Artery Disease/

4. Coronary Artery Disease/ or Coronary Disease/ or Coronary Angiography/

5. CAD.mp.

6. myocardial infarction.mp. or Myocardial Infarction/

7. myocardial ischemia.mp. or Myocardial Ischemia/

8. Aquilion.mp.

9. Prime.mp.

10. Toshiba.mp.

11. 1 or 2

12. 3 or 4 or 5 or 6 or 7

13. 8 or 9 or 10

14. 11 and 12 and 13

15. cost*.mp.

16. economic*.mp.

17. 15 or 16

18. 14 and 17

19. limit 18 to english language

20. limit 19 to yr="2012 ‑Current"

Cochrane Database of Systematic Reviews: Issue 10 of 12, October 2015

Cochrane Central Register of Controlled Trials: Issue 9 of 12, September 2015

Database of Abstracts of Reviews of Effect: Issue 2 of 4, April 2015

Cochrane Methodology Register: Issue 3 of 4, July 2012

Health Technology Assessment Database: Issue 3 of 4, July 2015

NHS Economic Evaluation Database: Issue 2 of 4, April 2015

  1. CT

  2. computed tomography

  3. Coronary Artery Disease

  4. Coronary Disease or Coronary Angiography

  5. CAD

  6. myocardial infarction

  7. myocardial ischemia

  8. Aquilion

  9. Prime

  10. Toshiba

  11. #1 or #2

  12. #3 or #4 or #5 or #6 or #7

  13. #8 or #9 or #10

  14. #11 and #12 and #13

  15. cost*

  16. economic*

  17. #15 or #16

  18. #14 and #17 Publication Year from 2012 to 2015

Evidence selection

Evidence was selected based on the following criteria:

  • Population: patients with suspected or known CAD with 1 of the following conditions:

    • obesity

    • high levels of coronary calcium (greater than 400 Agatston units [AU])

    • high heart rates (more than 65 beats per minute) that cannot be lowered with drugs

    • arrhythmias (irregular heart rhythm)

    • stents

    • previous bypass grafts.

  • Intervention: Toshiba Aquilion PRIME.

  • Comparator: ICA, cardiac MRI, SPECT, ECHO.

  • Outcomes: diagnostic test accuracy, indeterminacy, radiation exposure and clinical outcomes including side effects associated with the use of contrast medium, major adverse cardiac events, or mortality.

  • Exclusion criteria: case studies, editorials, letters, reviews, conference proceedings/abstracts, animal studies, non‑English language studies, studies not using the Aquilion PRIME.

For the clinical evidence

  • Total number of publications reviewed: 1972

  • Total number of publications considered relevant: 0

  • Total number of publications selected for inclusion in this briefing: 0

For the economic evidence

  • Total abstracts: 21

  • Duplicates: 1

  • Abstracts reviewed: 20

  • Full papers reviewed: 0

  • Studies for review: 0